Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy

BACKGROUND: Oxaliplatin is a chemotherapy agent active against digestive tumors. Peripheral neuropathy is one of the most important dose-limiting toxicity of this drug. It occurs in around 60–80% of the patients, and 15% of them develop severe neuropathy. The pathophysiology of oxaliplatin neurotoxi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Cancer
Autors principals: Sereno, María, Gutiérrez-Gutiérrez, Gerardo, Rubio, Juan Moreno, Apellániz-Ruiz, María, Sánchez-Barroso, Lara, Casado, Enrique, Falagan, Sandra, López-Gómez, Miriam, Merino, María, Gómez-Raposo, César, Rodriguez-Salas, Nuria, Tébar, Francisco Zambrana, Rodríguez-Antona, Cristina
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2017
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5248487/
https://ncbi.nlm.nih.gov/pubmed/28103821
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-3031-5
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars